Mismatch repair and p53 independently affect sensitivity to N-(2- chloroethyl)-N'-cyclohexyl-N-nitrosourea

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 671-680

  Aquilina, Gabriele ^a   Ceccotti, Sabrina ^a   Martinelli, Simone ^a   Soddu, Silvia ^b   Crescenzi, Marco ^a,b   Branch, Pauline ^c   Karran, Peter ^c   Bignami, Margherita ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROTEIN P53;

AMINO ACID SUBSTITUTION; ARTICLE; CELL KILLING; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

AMINO ACID SUBSTITUTION; APOPTOSIS; BASE PAIR MISMATCH; BCL-2-ASSOCIATED X PROTEIN; CARRIER PROTEINS; CELL CYCLE; CELL SURVIVAL; CODON; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; GENES, P53; HUMANS; IN SITU NICK-END LABELING; LOMUSTINE; METHYLNITROSOUREA; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033969484     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Ludlum, D. B. DNA alkylation by haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat. Res., 233: 117-126, 1990.
2. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res., 50: 6119-6129, 1990.
3. Matijasevic, Z., Boosalis, M., Mackay, W., Samson, L., and Ludlum, D. B. Protection against chloroethylnitrosourea cytotoxicity by eukaryotic 3-methyladenine DNA glycosylase. Proc. Natl. Acad. Sci. USA, 90: 11855-11859, 1993.
4. 6-alkylguanine DNA adducts in glioma-derived human cells resistant to the cytotoxic and cytogenetic effects of 1,3-bis (2-chloroethyl)-1-nitrosourea. Carcinogenesis (Lond.), 7: 879-883, 1986.
5. Engelward, B. P., Dreslin, A., Christensen, J., Huszar, D., Kurahara, C., and Samson, L. Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing. EMBO J., 15: 945-952, 1996.
6. Allan, M. J., Engelward, B. P., Dreslin, A. J., Wyatt, M. D., Tomasz, M., and Samson, L. D. Mammalian 3-methyladenine DNA glycosylase protects against the toxicity and clastogenicity of certain chemotherapeutic DNA cross-linking agents. Cancer Res., 58: 3965-3973, 1998.
7. 6-methylguanine-DNA methyltransferase in a DNA excision repair-deficient Chinese hamster ovary cell line and its response to certain alkylating agents. Cancer Res., 52: 32-35, 1992.
8. Aquilina, G., Ceccotti, S., Martinelli, S., Hampson, R., and Bignami, M. CCNU sensitivity in mismatch repair defective human cells. Cancer Res., 58: 135-141, 1998.
9. Gottlieb, T., and Oren, M. p53 in growth control and neoplasia. Biochim. Biophys. Acta, 1287: 77-102, 1996.
10. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
11. Lowe, S. W., Bodis, S., MaClatchey, A., Remington, L., Ruley, H. E., Fisher, D., Housman, D. E., and Jack, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
12. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and -independent pathways. Nature (Lond.), 362: 849-852, 1993.
13. O'Connor, P., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776-4780, 1993.
14. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Magrath, I., Kohn, K. W., and O' Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
15. Vasey, P. A., Jones, N. A., Jenkins, S., Dive, C., and Brown, R. Cisplatin, campothecin, and Taxol sensitivities of cells with p53-associated multidrug resistance. Molecular Pharmacol., 50: 1536-1540, 1996.
16. McIlwrath, A., Vasey, P., Ross, G., and Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54: 3718-3722, 1994.
17. Lowe, S. W. Cancer therapy and p53. Curr. Opin. Oncol., 7: 547-553, 1995.
18. Fan, S., Smith, M., Rivet, D. n., Duba, D., Zhan, Q., Kohn, K., Fornace, A. J., and O'Connor, P. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
19. Brachman, D., Beckett, M., Graves, D., Haraf, D., Vokes, E., and Weichselbaum, R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 15: 3667-3669, 1993.
20. Hawkins, D., Demers, G., and Galloway, D. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892-898, 1996.
21. Gupta, M., Fan, S., Zhan, Q., Kohn, K., O'Connor, P., and Pommier, Y. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin. Cancer Res., 3: 1653-1660, 1997.
22. Aquilina, G., Hess, P., Fiumicino, S., Ceccotti, S., and Bignami, M. A mutator phenotype characterizes one of two complementation groups in human cells tolerant to methylation damage. Cancer Res., 55: 2569-2575, 1995.
23. Takeuchi, S., Bartram, C., Ludwig, R., Royer-Pokora, B., Schneider, S., Imamura, J., and Koeffler, H. P. Mutations of p53 in Wilms' tumors. Mod. Pathol., 8: 483-487, 1995.
24. Michalovitz, D., Halevy, O., and Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62: 671-680, 1990.
25. Brown, R., Chigston, C., Burns, P., Edlin, A., Vasey, P., Vojtesek, B., and Kaye, S. B. Increased accumulation of p53 protein in cis-platin resistant ovarian cell lines. Int. J. Cancer, 55: 678-684, 1993.
26. 6-methylguanine-DNA methyltransferase expression in acquired resistance to methylating agents in human cells. J. Biol. Chem., 272: 28596-28606, 1997.
27. Humbert, O., Fiumicino, S., Aquilina, G., Branch, P., Oda, S., Zijno, A., Karran, P., and Bignami, M. Mismatch repair and differential sensitivity of mouse and human cells to DNA methylating agents. Carcinogenesis (Lond.), 20: 205-214, 1999.
28. McLaughlin, K., Stephens, I., McMahon, N., and Brown, R. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line. Cancer Res., 51: 2242-2245, 1991.
29. Siddik, Z., Mims, B., Lozano, G., and Thai, G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res., 58: 698-703, 1998.
30. DiCioccio, R. A., Werness, B. A., Peng, R., Allen, H. J., and Piver, M. S. Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer Genet. Cytogenet., 105: 93-102, 1998.
31. Slebos, R. J. C., Baas, I. O., Clement, M., Polak, M., Mulder, J-W., van den Berg, F. M., Hamilton, S. R., and Offerhaus, G. J. A. Clinical and pathological associations with p53 tumor-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br. J. Cancer, 74: 165-171, 1996.
32. Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahusa, N., Issa, J-P., Markowitz, S., Willson, J. K., Hamilton, S. R., Kinzler, K. W., Kane, M. F., Kolodner, R. D., Vogelstein, B., Kunkel, T. A., and Baylin, S. B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870-6875, 1998.
33. Veigl, M. L., Modrich, P. L., and Markowitz, S. D. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc. Natl. Acad. Sci. USA, 95: 8698-8702, 1998.
34. Esteller, M., Levine., R., Baylin, S., Ellenson, L., and Herman, J. G. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene, 17: 2413-2417, 1998.
35. Strathdee, G., MacKean, M. J., Illand, M., and Brown, R. A role for methylation in the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene, 18: 2335-2341, 1999.
36. Malkhosyan, S., Rampino, N., Yamamoto, H., and Perucho, M. Frameshift mutator mutations. Nature (Lond.), 382: 499-500, 1996.
37. Yamamoto, H., Sawai, H., Weber, T. K., Rodriguez-Bigas, M. A., and Perucho, M. Somatic frameshift mutations in DNA mismatch repair genes and proapoptosis genes in hereditary nonpolyposis colorectal cancer. Cancer Res., 58: 997-1003, 1998.
38. Kim, H., Jen, J., Vogelstein, B., and Hamilton, S. R. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am. J. Pathol., 145: 148-156, 1994.
39. Hainaut, P., Hernandez, T., Robinson, A., Rodriguez-Tome, P., Flores, T., Hollstein, M., Harris, C. C., and Montesano, R. IARC database of p53 mutations in human tumors and cell lines: updated compilation, revised formats and new visualization tools. Nucleic Acids Res., 26: 205-213.
40. Aoki, H., Ohnishi, K., Wang, X., Takahashi, T., Ohnishi, T., Nakamura, M., and Sakaki, T. p53-independent WAF1 induction by ACNU in human glioblastoma cells. Mol. Carcinog., 21: 171-176, 1998.